SBIR TOPIC 081: ADJUVANT DEVELOPMENT FOR VACCINES AGAINST INFECTIOUS OR IMMUNE-MEDIATED DISEASES Solicitation ID/Procurement Identifier: PHS20201 Ultimate Completion Date: Wed Aug 31 17:00:00 GMT 2022
IntroductionThe National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), of the Department of Health and Human Services (DHHS) supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases.
Award Notice
DISEASES (NIAID): Topic 113 - Development of a Simian Immunodeficiency Virus (SIV) and Simian Human Immunodeficiency Virus (SHIV) DatabaseTopic 114 - Point-of-Care HIV Viral Load, Drug Resistance, and Adherence AssaysTopic 115 - Development of Diagnostics to Differentiate HIV Infection from Vaccine-Induced SeropositivityTopic 116 - Adjuvant Discovery for Vaccines for Infectious and Immune-Mediated DiseasesTopic 117 - Adjuvant Development for Vaccines
, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases.
The infectious diseases and immune mediated diseases communities have become a data-intense enterprise and a priority for NIAID is to transform this data into knowledge to understand the pathogenesis, transmission, evolution of the pathogen, pathogen-host interactions and the host response to infectious diseases and inform the development of new and improved diagnostics, therapeutics, and vaccines.
Key research areas include newly emerging and re-emerging infectious diseases such as tuberculosis and influenza, HIV/AIDS, biodefense, and immune-mediated diseases including asthma and allergy. Please register by completing this survey.Each company is limited to four attendees. There is a 400-person registration limit. This event substitutes for the NIH Small Business Program Office's March 2022 1-on-1 consultations.
